Idazoxan and CH-38083 affect gastric secretion by inhibiting alpha-2 adrenoceptors at vagal and sympathetic pathways.
Del Tacca
M
M
Institute of Medical Pharmacology, University of Pisa, Italy.
Blandizzi
C
C
Bernardini
M C
MC
Vizi
S E
SE
D000319:Adrenergic beta-Antagonists / Q000494:pharmacology*; D000818:Animals; D001599:Berberine / Q000031:analogs & derivatives / Q000494:pharmacology*; D001600:Berberine Alkaloids / Q000494:pharmacology*; D004146:Dioxanes / Q000494:pharmacology*; D004147:Dioxins / Q000494:pharmacology*; D004558:Electric Stimulation; D005753:Gastric Mucosa / Q000187:drug effects / Q000378:metabolism*; D019329:Idazoxan; D066298:In Vitro Techniques; D009434:Neural Pathways / Q000187:drug effects / Q000378:metabolism*; D051381:Rats; D011942:Receptors, Adrenergic, alpha / Q000187:drug effects / Q000378:metabolism*; D013270:Stomach / Q000187:drug effects / Q000294:innervation; D013564:Sympathetic Nervous System / Q000187:drug effects; D014630:Vagus Nerve / Q000187:drug effects / Q000378:metabolism / Q000502:physiology
D000319:Adrenergic beta-Antagonists; D001600:Berberine Alkaloids; D004146:Dioxanes; D004147:Dioxins; D011942:Receptors, Adrenergic, alpha; D001599:Berberine; C048886:7,8-(methylenedioxy)-14-hydroxyberbane; D019329:Idazoxan